Twist Bioscience adds to gene designing capability by buying Genome Compiler

7 April 2016
mergers-acquisitions-big

Private DNA synthesis firm Twist Biotech has bought Genome Compiler, an Israel-based company which provides software for genetic engineers, molecular and synthetic biologists.

USA-based Twist has a DNA manufacturing process featuring a silicon platform which allows it to produce synthetic biology tools on a vast scale including synthetic biology tools, oligonucleotide pools and variant libraries.

Its DNA is already used by many of the world’s big pharma companies along with other members of the synthetic and molecular biology communities to further their research.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology